We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00235482
First Posted: October 10, 2005
Last Update Posted: May 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Viralytics
October 7, 2005
October 10, 2005
May 10, 2017
August 2005
Not Provided
Safety profile of treatment, characterisation of adverse events
Same as current
Complete list of historical versions of study NCT00235482 on ClinicalTrials.gov Archive Site
Efficacy - clinical response of injected and non-injected tumours
Same as current
Not Provided
Not Provided
 
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malignant Melanoma
Drug: Coxsackievirus A21
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3
Not Provided
Not Provided

Inclusion Criteria:

  • stage IV melanoma (AJCC classification)
  • minimum of 2 sc metastases
  • failure or refusal of standard chemotherapy
  • ECOG score of 0 or 1
  • other

Exclusion Criteria:

  • metastatic CNS disease
  • ocular or mucosal melanoma
  • immunodeficiency
  • splenectomy
  • other
Sexes Eligible for Study: All
21 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT00235482
PSX-X-02
Not Provided
Not Provided
Not Provided
Not Provided
Viralytics
Not Provided
Not Provided
Viralytics
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP